Leaflet CYRDANAX 20mg / ml powder for solution for infusion

Indicated for: protection against chemotherapy or radiotherapy toxicity

Route of administration: infusion

Substance: dexrazoxane (antidote)

ATC: V03AF02 (Various | All other therapeutic products | Detoxifying agents for antineoplastic treatment)

Dexrazoxane is a medication used to protect against anthracycline-induced cardiotoxicity, a type of chemotherapy used in cancer treatment. It works by chelating iron ions, reducing the formation of free radicals that can damage the heart muscle.

The medication is administered intravenously, usually before anthracycline administration, under the supervision of an oncologist.

Side effects may include nausea, vomiting, decreased blood cell counts, or injection site reactions. In rare cases, severe allergic reactions may occur.

Patients should be closely monitored during treatment, and pregnant or breastfeeding women should consult a specialist before use.

General data about CYRDANAX 20mg / ml

  • Substance: dexrazoxane
  • Date of latest medicines list: 01-07-2020
  • Product code: W59811001
  • Concentration: 20mg / ml
  • Pharmaceutical form: powder for solution for infusion
  • Quantity: 1
  • Product type: Generic medicine
  • Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

  • Manufacturer: PHARMASELECT INTERNATIONAL BETEILIGUNGS GMBH - AUSTRIA
  • Holder: PHARMASELECT INTERNATIONAL BETEILIGUNGS GMBH - AUSTRIA
  • Number: 11136/2018/01
  • Shelf life: after packaging for sale-2 years;after reconstitution-it is used immediately

Concentrations available for dexrazoxane

  • 20mg/ml
  • 500mg